![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 16, 2014 6:07:23 PM
Amgen purchased T-VEC from Biovex for $425M cash up front with milestone incentives totaling $1B in 2011:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109088921
The efficacy and safety profile for T-VEC as a monotherapy was similar, but not quite as good as ONCS' ImmunoPulse.
The recent T-VEC/Yervoy combination results are very good and there is much excitement around the ImmunoPulse/Keytruda PD1 combination which may offer even better efficacy without side effects.
Why would you not be excited about such a combination? Clearly, leading experts in the field of oncology and immunology are. What technology interests you more and why?
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM